Macrogol Neuraxpharm

Macrogol 3350, the active ingredient in Macrogol Neuraxpharm, is an osmotic laxative presented as an oral solution for oral use. It works by retaining water in the intestinal lumen, softening stool and facilitating bowel movements in patients with constipation, including adults and children. The formulation also contains sodium hydrogen carbonate, potassium chloride and sodium chloride to maintain electrolyte balance.

GNH USA supplies Macrogol Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Macrogol Neuraxpharm, an osmotic laxative, is used to manage conditions involving impaired bowel motility or hard stools.

- Chronic constipation: softens stool and promotes regular bowel movements in adults and children. - Opioid‑induced constipation: counteracts opioid‑related reduction in intestinal water content to restore normal defecation. - Functional constipation: improves stool consistency and frequency in patients with functional bowel disorders.

Macrogol Neuraxpharm may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating: sensation of fullness or swelling in the abdomen. - Flatulence: increased intestinal gas leading to discomfort. - Nausea: feeling of unease or urge to vomit. - Abdominal cramps: intermittent painful contractions of the gut. - Diarrhoea: loose, watery stools occurring with higher doses. - Thirst: increased desire for fluids.

Serious or Rare Side Effects: - Electrolyte imbalance: abnormal levels of sodium, potassium or chloride. - Severe dehydration: excessive loss of body water. - Allergic reaction: rash, itching, swelling or difficulty breathing. - Intestinal obstruction: worsening blockage in patients with existing obstruction. - Severe abdominal pain: intense, persistent pain requiring medical attention.

Before initiating therapy with Macrogol Neuraxpharm, consider the following precautions.

- Assess hydration status: ensure the patient is adequately hydrated to reduce risk of dehydration. - Monitor electrolytes: check sodium, potassium and chloride levels, especially in long‑term use. - Adjust dose in renal impairment: reduce dosage or increase monitoring in patients with reduced kidney function. - Use cautiously in inflammatory bowel disease: avoid if active obstruction or severe disease is present. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Macrogol Neuraxpharm can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: may reduce the laxative effect of macrogol. - Opioid analgesics: can exacerbate constipation, requiring combined therapy. - Mineral oil: increased risk of aspiration and reduced effectiveness.

Moderate Interactions (Monitor Closely): - Diuretics: potential for additive electrolyte disturbances. - ACE inhibitors: may affect potassium balance when combined. - NSAIDs: increased risk of gastrointestinal irritation when used together.